Coursera, Inc. (NYSE:COUR) is one of the Best All-Time Low Stocks to Buy in 2026. On April 24, Jeffery Silber from BMO ...

Is COUR a good stock to buy? We came across a bullish thesis on Coursera, Inc. on r/ValueInvesting by Vino-Bins. In this ...

We believe Coursera (COUR) stock is worth considering: It is growing, generating cash, and offered at a substantial valuation discount. Companies like this can utilize cash to stimulate further ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted Cour Pharmaceuticals orphan drug ...

The average one-year price target for Coursera (NYSE:COUR) has been revised to $8.22 / share. This is a decrease of 16.31% from the prior estimate of $9.82 dated April 12, 2026. The price target is an ...

Online educational provider Coursera (COUR) has seen its shares surge 27% in the last five days following surprisingly strong Q2 results that beat top-and-bottom-line expectations. After Q1’s ...

COUR stock's significant drop after revising FY24 revenue guidance downward is seen as an overreaction. Valued at around $1 billion, COUR is in value territory with $719 million in cash, no debt, and ...

Cour Pharmaceuticals, the Chicago-based clinical-stage biotechnology company, says its first patient has been dosed in the phase 1b/2a clinical trial of a treatment that it hopes will address ...

Steve P. Miller, PhD, has spent much of his career figuring out how to shut off autoimmune responses when he observed dying cells acting as carriers of autoantigens that could modulate the immune ...